Overview
Overview
Parent Cell: Akira Osteoblasts differentiated from UCT-WJ-MSCs | Osteogenic growth factors and miRNAs for osteoblast repair and regeneration
| Stats | Details |
|---|---|
| Particle Count | ≥ 1.1 × 10¹¹ exosomes per vial (NTA-validated) |
| Growth Factors | BMP-2, BMP-7, TGF-β1, VEGF, IGF-1, FGF-2, Wnt3a, OPG |
| miRNA Cargo | miR-2861, miR-3960, miR-21, miR-146a, miR-34a |
| Identity Markers | RUNX2+, Osteocalcin+, Osteopontin+, ALP+ |
| Storage | −20 °C; 4 °C post-thaw ≤ 72 hrs; do not refreeze |
| Regulatory Status | For Educational Purposes Only |
Definition
What Are Exosomes?
Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.
The Akira Osteoblast Exosome Matrix is produced from osteoblasts differentiated from UCT-WJ-MSCs using an osteogenic induction protocol (dexamethasone, ascorbic acid, β-glycerophosphate) under cGMP conditions. Osteoblast identity is confirmed by RUNX2 expression (master osteogenic transcription factor), alkaline phosphatase (ALP) activity, and osteocalcin/osteopontin secretion prior to exosome harvest.
Osteoblast-derived exosomes are naturally enriched with BMP-2 and BMP-7 — the two most potent osteoinductive bone morphogenetic proteins — as well as Wnt pathway ligands that drive osteogenic differentiation of mesenchymal progenitors. The secretome delivers a complementary panel of bone anabolic growth factors including TGF-β1, IGF-1, and FGF-2. This preparation is designed for educational reference in the context of bone regeneration, fracture healing, osteoporosis, and spinal fusion research.[1]
Process
Mechanism of Action
Osteogenic Differentiation Induction (BMP Signaling): BMP-2 and BMP-7 bind BMPR1/BMPR2 receptors on mesenchymal progenitors, activating SMAD1/5/8 signaling and driving RUNX2 transcription — the master switch for osteoblastic commitment. This is the same molecular mechanism exploited by recombinant BMP-2 (rhBMP-2) in clinical spinal fusion — delivered here within an exosome matrix that provides sustained, protected cargo delivery alongside a full secretome complement.
Wnt Pathway Activation & Bone Anabolism: Wnt3a cargo activates β-catenin signaling in osteoblast progenitors, promoting proliferation and inhibiting adipogenic differentiation of MSCs. miR-2861 suppresses HDAC5, enhancing Runx2 stability. miR-3960 drives Hoxa2 suppression, further promoting osteogenic over chondrogenic differentiation. Together these mechanisms support robust bone anabolic activity.
Osteoclast Suppression & Bone Homeostasis: OPG (osteoprotegerin) from the osteoblast secretome acts as a decoy receptor for RANKL, blocking osteoclast differentiation and activity. miR-34a suppresses osteoclast-associated gene expression. This shifts the osteoblast:osteoclast balance toward bone formation — directly relevant to osteoporosis, periprosthetic bone loss, and conditions of excessive bone resorption.
Fracture Callus Vascularization: VEGF and FGF-2 in the secretome drive angiogenesis into the fracture callus — a prerequisite for bone remodeling and osteoblast survival within healing bone. IGF-1 promotes callus maturation and mineralisation. This angiogenic-osteogenic coupling is essential to normal fracture repair and is impaired in delayed union and non-union fractures.[2]
Biomarkers
Key Molecular Cargo
| Molecule / miRNA | Therapeutic Function |
|---|---|
| BMP-2 | Primary osteoinductive factor; SMAD1/5/8 → RUNX2 activation; osteoblastic commitment of MSC progenitors |
| BMP-7 | Osteoinductive; chondrocyte and bone differentiation; cartilage-bone interface repair |
| RUNX2 cargo | Master osteogenic transcription factor; osteoblast identity and differentiation driver |
| OPG | Osteoprotegerin — RANKL decoy receptor; osteoclast suppression; bone homeostasis |
| TGF-β1 | Osteoblast proliferation and ECM production; periosteal progenitor activation |
| IGF-1 | Bone anabolism; osteoblast survival; callus maturation and mineralisation |
| miR-2861 | HDAC5 suppression; RUNX2 stability enhancement; pro-osteogenic epigenetic regulation |
| miR-3960 | Hoxa2 suppression; osteogenic lineage commitment reinforcement |
| miR-21 | Osteoblast survival; RANKL modulation; bone remodeling regulation |
| ALP (marker) | Alkaline phosphatase — osteoblast activity marker; bone mineralisation enzyme |
Applications
Therapeutic Applications
???
Evidence
Clinical & Preclinical Evidence
???